Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea.
暂无分享,去创建一个
M. Pfisterer | P. Buser | C. Schindler | C. Mueller | B. Martina | K. Laule-Kilian | A. Perruchoud | A. Scholer
[1] A. Hoes,et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. , 2005, European heart journal.
[2] J. Hollander,et al. B-type natriuretic peptide and renal function in the diagnosis of heart failure: an analysis from the Breathing Not Properly Multinational Study. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[3] T. McDonagh,et al. Retrospective analysis of the cost-effectiveness of using plasma brain natriuretic peptide in screening for left ventricular systolic dysfunction in the general population. , 2003, Journal of the American College of Cardiology.
[4] P. Buser,et al. B-type natriuretic peptide (BNP): can it improve our management of patients with congestive heart failure? , 2002, Swiss medical weekly.
[5] M. Redfield,et al. Heart failure--an epidemic of uncertain proportions. , 2002, The New England journal of medicine.
[6] Douglas W Mahoney,et al. Plasma brain natriuretic peptide concentration: impact of age and gender. , 2002, Journal of the American College of Cardiology.
[7] J. Hollander,et al. B-Type Natriuretic Peptide and Clinical Judgment in Emergency Diagnosis of Heart Failure: Analysis From Breathing Not Properly (BNP) Multinational Study , 2002, Circulation.
[8] Alan S Maisel,et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. , 2002, The New England journal of medicine.
[9] R. Pistelli,et al. Exacerbated chronic obstructive pulmonary disease: a frequently unrecognized condition , 2002, Journal of internal medicine.
[10] E. Antman,et al. ACC/AHA PRACTICE GUIDELINES ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: Executive Summary , 2002 .
[11] L. Morrison,et al. Utility of a rapid B-natriuretic peptide assay in differentiating congestive heart failure from lung disease in patients presenting with dyspnea ☆ , 2002 .
[12] John A Spertus,et al. Confirmation of a heart failure epidemic: findings from the Resource Utilization Among Congestive Heart Failure (REACH) study. , 2002, Journal of the American College of Cardiology.
[13] M. Vogeser,et al. Role of brain natriuretic peptide in risk stratification of patients with congestive heart failure. , 2001, Journal of the American College of Cardiology.
[14] D. Dusser,et al. Brain natriuretic peptide blood levels in the differential diagnosis of dyspnea. , 2001, Chest.
[15] K. Swedberg,et al. Guidelines for the diagnosis and treatment of chronic heart failure. , 2001, European heart journal.
[16] J. Carroll,et al. Heart Failure With a Normal Ejection Fraction: Is Measurement of Diastolic Function Necessary to Make the Diagnosis of Diastolic Heart Failure? , 2001, Circulation.
[17] L. Lenert,et al. A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study. , 2001, Journal of the American College of Cardiology.
[18] L. Lenert,et al. Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting. , 2001, Journal of the American College of Cardiology.
[19] U. Dohrmann,et al. Gene Expression of Brain Natriuretic Peptide in Isolated Atrial and Ventricular Human Myocardium: Influence of Angiotensin II and Diastolic Fiber Length , 2000, Circulation.
[20] H. Tunstall-Pedoe,et al. Biochemical detection of left-ventricular systolic dysfunction , 1998, The Lancet.
[21] S. Ogston,et al. Cross sectional study of contribution of clinical assessment and simple cardiac investigations to diagnosis of left ventricular systolic dysfunction in patients admitted with acute dyspnoea , 1997, BMJ.
[22] M. Sorrentino,et al. Causes of congestive heart failure. Prompt diagnosis may affect prognosis. , 1997, Postgraduate medicine.
[23] Milton C. Weinstein,et al. Recommendations for Reporting Cost-effectiveness Analyses , 1996 .
[24] M C Weinstein,et al. Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and Medicine. , 1996, JAMA.
[25] M. Weinstein,et al. Recommendations of the Panel on Cost-effectiveness in Health and Medicine. , 1996, JAMA.
[26] H. Itoh,et al. Rapid ventricular induction of brain natriuretic peptide gene expression in experimental acute myocardial infarction. , 1995, Circulation.
[27] B. Gersh,et al. The utility of clinical, electrocardiographic, and roentgenographic variables in the prediction of left ventricular function. , 1995, The American journal of cardiology.
[28] K. Kugiyama,et al. Localization and Mechanism of Secretion of B‐Type Natriuretic Peptide in Comparison With Those of A‐Type Natriuretic Peptide in Normal Subjects and Patients With Heart Failure , 1994, Circulation.
[29] A. Richards,et al. Plasma brain natriuretic peptide in assessment of acute dyspnoea , 1994, The Lancet.
[30] R. Wuerz,et al. Effects of prehospital medications on mortality and length of stay in congestive heart failure. , 1992, Annals of emergency medicine.